Daozhi Xu1, Peixin Dong1, Ying Xiong2, Rui Chen2, Yosuke Konno1, Kei Ihira1, Junming Yue3,4, Hidemichi Watari1. 1. Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan. 2. Department of Gynecology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. 3. Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, United States. 4. Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Abstract
BACKGROUND: Poorly differentiated endometrioid adenocarcinoma and serous adenocarcinoma represent an aggressive subtype of endometrial cancer (EC). Programmed death-ligand-1 (PD-L1) was known to exhibit a tumor cell-intrinsic function in mediating immune-independent tumor progression. However, the functional relevance of tumor cell-intrinsic PD-L1 expression in aggressive EC cells and the mechanisms regulating its expression remain unknown. METHODS: PD-L1 expression in 65 EC tissues and 18 normal endometrium samples was analyzed using immunohistochemical staining. The effects of PD-L1 on aggressive EC cell growth, migration and invasion were investigated by cell functional assays. Luciferase reporter assays were used to reveal the microRNA-216a (miR-216a)-dependent mechanism modulating the expression of PD-L1. RESULTS: Positive PD-L1 expression was identified in 84% of benign cases but only in 12% of the EC samples, and the staining levels of PD-L1 in EC tissues were significantly lower than those in the normal tissues. Higher PD-L1 expression predicts favorable survival in EC. Ectopic expression of PD-L1 in aggressive EC cells results in decreased cell proliferation and the loss of mesenchymal phenotypes. Mechanistically, PD-L1 exerts the anti-tumor effects by downregulating MCL-1 expression. We found that PD-L1 levels in aggressive EC cells are regulated by miR-216a, which directly targets PD-L1. We further identified a mechanism whereby the long non-coding RNA MEG3 represses the expression of miR-216a, thereby leading to increased PD-L1 expression and significant inhibition of cell migration and invasion. CONCLUSION: These results reveal an unappreciated tumor cell-intrinsic role for PD-L1 as a tumor suppressor in aggressive EC cells, and identify MEG3 and miR-216a as upstream regulators of PD-L1.
BACKGROUND: Poorly differentiated endometrioid adenocarcinoma and serous adenocarcinoma represent an aggressive subtype of endometrial cancer (EC). Programmed death-ligand-1 (PD-L1) was known to exhibit a tumor cell-intrinsic function in mediating immune-independent tumor progression. However, the functional relevance of tumor cell-intrinsic PD-L1 expression in aggressive EC cells and the mechanisms regulating its expression remain unknown. METHODS: PD-L1 expression in 65 EC tissues and 18 normal endometrium samples was analyzed using immunohistochemical staining. The effects of PD-L1 on aggressive EC cell growth, migration and invasion were investigated by cell functional assays. Luciferase reporter assays were used to reveal the microRNA-216a (miR-216a)-dependent mechanism modulating the expression of PD-L1. RESULTS: Positive PD-L1 expression was identified in 84% of benign cases but only in 12% of the EC samples, and the staining levels of PD-L1 in EC tissues were significantly lower than those in the normal tissues. Higher PD-L1 expression predicts favorable survival in EC. Ectopic expression of PD-L1 in aggressive EC cells results in decreased cell proliferation and the loss of mesenchymal phenotypes. Mechanistically, PD-L1 exerts the anti-tumor effects by downregulating MCL-1 expression. We found that PD-L1 levels in aggressive EC cells are regulated by miR-216a, which directly targets PD-L1. We further identified a mechanism whereby the long non-coding RNA MEG3 represses the expression of miR-216a, thereby leading to increased PD-L1 expression and significant inhibition of cell migration and invasion. CONCLUSION: These results reveal an unappreciated tumor cell-intrinsic role for PD-L1 as a tumor suppressor in aggressive EC cells, and identify MEG3 and miR-216a as upstream regulators of PD-L1.
Authors: Evan J Lipson; Jeremy G Vincent; Myriam Loyo; Luciane T Kagohara; Brandon S Luber; Hao Wang; Haiying Xu; Suresh K Nayar; Timothy S Wang; David Sidransky; Robert A Anders; Suzanne L Topalian; Janis M Taube Journal: Cancer Immunol Res Date: 2013-07 Impact factor: 11.151
Authors: Zaibo Li; Amy S Joehlin-Price; Jennifer Rhoades; Martins Ayoola-Adeola; Karin Miller; Anil V Parwani; Floor J Backes; Ashley S Felix; Adrian A Suarez Journal: Int J Gynecol Cancer Date: 2018-01 Impact factor: 3.437
Authors: Irene Papatheodorou; Pablo Moreno; Jonathan Manning; Alfonso Muñoz-Pomer Fuentes; Nancy George; Silvie Fexova; Nuno A Fonseca; Anja Füllgrabe; Matthew Green; Ni Huang; Laura Huerta; Haider Iqbal; Monica Jianu; Suhaib Mohammed; Lingyun Zhao; Andrew F Jarnuczak; Simon Jupp; John Marioni; Kerstin Meyer; Robert Petryszak; Cesar Augusto Prada Medina; Carlos Talavera-López; Sarah Teichmann; Juan Antonio Vizcaino; Alvis Brazma Journal: Nucleic Acids Res Date: 2020-01-08 Impact factor: 16.971